Focus Partners Wealth
RARE icon

Focus Partners Wealth’s Ultragenyx Pharmaceutical RARE Stock Holding History

Focus Partners Wealth’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840K Buy
+25,157
New +$625K ﹤0.01% 1715
2024
Q4 		– Sell
-5,005
Closed -$278K – 1964
2024
Q3 		$278K Buy
+5,005
New +$255K ﹤0.01% 1354

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Focus Partners Wealth's RARE Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 25,157 shares worth $840K. The stake represents ﹤0.01% of the portfolio and ranks #1715 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in RARE as recently as Q3 2024.

Focus Partners Wealth first reported a position in RARE in Q3 2024 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Focus Partners Wealth held 25,157 shares of Ultragenyx Pharmaceutical worth $840K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Focus Partners Wealth position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1715 holding.
  • Focus Partners Wealth first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 2 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.